COMPANY PROFILE

RyboDyn

Explore full profile

Scientists are known for their objectivity, persistence, and analytic thinking

San Diego, United StatesFounded 2022Biotech & Life Sciences

Valuation $50–100M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About RyboDyn

RyboDyn is dedicated to advancing the development of revolutionary medicines by leveraging cutting-edge scientific breakthroughs. The company operates in the pharmaceutical and biotechnology sectors, focusing on creating new methods and treatments that promise significant improvements in healthcare. RyboDyn serves laboratories worldwide, providing them with the tools and knowledge to develop life-changing medicines. The business model revolves around offering credible solutions and pioneering advancements that adhere to the highest standards, ensuring impactful results. Revenue is generated through partnerships with research institutions and pharmaceutical companies, as well as through the commercialization of their proprietary methods and treatments. RyboDyn's approach combines scientific rigor with creative thinking, positioning itself as a key player in the future of research medicine.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2022
Headquarters: San Diego, United States
Employees: 16
Open positions: None listed
Dealroom signal: 80.6/100
Industry: Health
Sub-industry: Pharmaceutical, BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

5 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANTOther financing	Jul 2026	$1.3M	—	US Department of War · Dow · Congressionally Directed Medical Research Programs	↗
SEEDOther financing	Mar 2026	$10M	$40M	Phase Two Ventures · SOSV · SeaX Ventures · Massive Tech Ventures	↗

Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

RyboDyn website traffic

Latest recorded traffic for RyboDyn is 750 monthly website visits, down 14.8% over the last three months. RyboDyn's team grew 14.3% over the past year.

Latest monthly visits750 3-month web change-14.8% 1-year team growth+14.3%

Monthly website visitsJan 2024–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
DTDraig TherapeuticsTargeted neuromodulators for major neuropsychiatric disorders treatment	Cardiff, United Kingdom	Operational	44	$217M	$700M
STSolve TherapeuticsTargeted cancer therapies enhancing safety and precision	San Diego, United States	Operational
EPEpitopeaTransatlantic cancer immunotherapeutics company	Montreal, Canada	Operational
AVAviadoBioPrecision gene therapies for neurodegenerative disorders	London, United Kingdom	Operational
ITIntegra TherapeuticsIntegra Therapeutics is a biotech company developing next-generation gene writing tools to cure genetic diseases	Barcelona, Spain	Operational
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
STStratus TherapeuticsDeveloping off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases	Natick, United States	Operational
ARArgusEyeReal-time, in-line sensor systems for biopharmaceutical manufacturing	Linköpings kommun, Sweden	Operational